There was only sufficient data to conduct this group comparison with one tracer but these results show that despite the limitations of using [18F]AV‐1451, this tracer is still able to differentiate PSP from PD patients using tau binding values. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.